Prostate cancer is the second leading cause of cancer-related death in Switzerland as well as in other western countries. For patients with advanced disease, ablation of androgens is regarded as optimal first-line treatment. But this treatment is palliative with a median duration of response of about 18 months and hormone refractory prostate cancer remains a challenge. Last year, two large rand...

PURPOSE Characterize the radiation response for transforming growth factor (TGF) alpha shedding in vitro and in vivo. We also report the shedding of TGF alpha by patients undergoing irradiation for hormone-refractory prostate cancer. EXPERIMENTAL DESIGN TGF alpha levels were determined by ELISA. DU145 xenografts were established on the flanks of athymic nu/nu mice. Expression of phospho-extra...

BACKGROUND Androgen receptor (AR) is the key molecule in androgen-refractory prostate cancer. Despite androgen ablative conditions, AR remains active and is necessary for the growth of androgen-refractory prostate cancer cells. Nuclear localization of AR is a prerequisite for its transcriptional activation. We examined AR localization in androgen-dependent and androgen-refractory prostate cance...

Advanced hormone-refractory prostate cancer is associated with poor prognosis and limited treatment options. Members of the pyrrolo-1,5-benzoxazepine (PBOX) family of compounds exhibit anti-cancer properties in cancer cell lines (including multi-drug resistant cells), ex vivo patient samples and in vivo mouse tumour models with minimal toxicity to normal cells. Recently, they have also been fou...

wnloade pose: This study aimed to characterize the preclinical activity of the first class of combinatorial, hondria-targeted, small molecule heat shock protein-90 (Hsp90) inhibitors, gamitrinibs, in models mone-refractory, drug-resistant, localized, and bone metastatic prostate cancer in vivo. erimental Design: Mitochondrial permeability transition, apoptosis, and changes in metabolic acwere e...

Downloa pose: This study aimed to characterize the preclinical activity of the first class of combinatorial, hondria-targeted, small molecule heat shock protein-90 (Hsp90) inhibitors, gamitrinibs, in models mone-refractory, drug-resistant, localized, and bone metastatic prostate cancer in vivo. erimental Design: Mitochondrial permeability transition, apoptosis, and changes in metabolic acwere e...

BACKGROUND The role of the epidermal growth factor receptor (ErbB1) in the progression of prostate cancer is incompletely understood. METHODS Tissue microarrays from hormone-naive and advanced androgen-independent tumors were used to investigate the role of ErbB1 in prostate cancer progression. RESULTS ErbB1 expression in tumor tissues was strongly associated with hormone-refractory status ...

ownloade pose: This study aimed to characterize the preclinical activity of the first class of combinatorial, hondria-targeted, small molecule heat shock protein-90 (Hsp90) inhibitors, gamitrinibs, in models mone-refractory, drug-resistant, localized, and bone metastatic prostate cancer in vivo. erimental Design: Mitochondrial permeability transition, apoptosis, and changes in metabolic acwere ...

Metastases from prostate cancer to the brain are very unusual and are seldom reported in the clinical literature. We report 2 cases of advanced stage prostate cancer with intracranial metastasis. One patient developed intracranial metastasis 5 years after step-up treatment. He had hormone refractory prostate cancer with a high level of prostate specific antigen (PSA). Unfortunately, he died of ...

The changing clinical dynamics of prostate cancer have resulted in a broadening of the research focus of the Genitourinary (GU) Cancer Committee of the Southwest Oncology Group (SWOG). Beginning with an emphasis on hormone-refractory disease in its early years, SWOG prostate cancer trials now cover the entire spectrum of the disease: localized, locally advanced, metastatic and hormone-refractor...